Quest Diagnostics Inc (NYSE:DGX) Director Gary M. Pfeiffer unloaded 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $55.95, for a total transaction of $559,500.00. Following the completion of the transaction, the director now directly owns 13,927 shares of the company’s stock, valued at approximately $779,216. Quest Diagnostics Inc (NYSE:DGX) net profit margin is 13.40% and weekly performance is 2.64%. On last trading day company shares ended up $57.18. Analysts mean target price for the company is $59.74. Quest Diagnostics Inc (NYSE:DGX) distance from 50-day simple moving average (SMA50) is1.50%.
CIGNA Corporation (NYSE:CI) CAO Mary T. Hoeltzel sold 3,000 shares of the stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $85.00, for a total transaction of $255,000.00. Following the completion of the sale, the chief accounting officer now directly owns 1,691 shares in the company, valued at approximately $143,735. CIGNA Corporation (NYSE:CI) shares advanced 1.04% in last trading session and ended the day on $86.49. Its return on assets is 2.70%. CIGNA Corporation (NYSE:CI) quarterly performance is 11.70%.
LifePoint Hospitals Inc (NASDAQ:LPNT) EVP John P. Bumpus unloaded 20,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $57.20, for a total transaction of $1,144,000.00. Following the transaction, the executive vice president now directly owns 97,901 shares of the company’s stock, valued at approximately $5,599,937. LifePoint Hospitals, Inc. (NASDAQ:LPNT) shares moved up 1.87% in last trading session and was closed at $57.61, while trading in range of $56.37 – $57.78 -. LifePoint Hospitals, Inc. (NASDAQ:LPNT) year to date (YTD) performance is 9.03%.
Charles River Laboratories (NYSE:CRL) Director George Massaro sold 1,620 shares of Charles River Laboratories stock in a transaction that occurred on Thursday, May 8th. The shares were sold at an average price of $52.70, for a total value of $85,374.00. Following the completion of the sale, the director now directly owns 16,510 shares in the company, valued at approximately $870,077. Charles River Laboratories (NYSE:CRL) ended the last trading day at $53.39. Company weekly volatility is calculated as 2.82% and price to cash ratio as 15.20. Charles River Laboratories (NYSE:CRL) showed a positive weekly performance of 5.22 %.
Leave a Reply